Mehmet Gökşin KARAMAN, Nihal YURTERİ, Esra ÖZDEMİR, Serhat KALA, HANDAN ANKARALI, Figen KARAMAN ELMACI, Ayten ERDOĞAN

Çocuk ve gençlerde risperidon tedavisine bağlı serum lipit profili

Amaç: Atipik antipsikotiklerin (AAP), AAP-ilişkili kilo artışı ile sonuçlanabilen metabolik bozukluğa neden olabile-ceği bildirilmiştir. Bu çalışmanın amacı risperidon ile tedavi edilen çocuk ve gençlerde trigliserit, kolesterol ve ağır-lık değişimlerini saptamak ve değerlendirmektir. Yöntem: Herhangi bir psikiyatrik bozukluk nedeniyle risperidon kullanan 80 hasta çalışmaya alınmıştır. Açlık total düşük dansiteli lipoprotein kolesterol (LDL-K), yüksek dansiteli lipoprotein kolesterol (HDL-K), total kolesterol (TK) ve trigliserit (TG) düzeyleri başlangıçta ve 12 aylık tedavi sonrası ölçülmüştür. Sonuçlar: Başlangıçtaki ortalama TG, TK, HDL-K ve LDL-K düzeyleri ile on iki aylık ortalama TG, TK, HDL-K ve LDL-K düzeyleri arasında anlamlı fark bulunmamıştır (sırasıyla p=0.341, p=0.135, p=0.414, p=0.411, p=0.707). Başlangıç ve 12. ay verileri yaş gruplarına göre karşılaştırıldığında yaş, cinsiyet, risperidon dozu ve serum TG, TK, LDL-K veya HDL-K düzeylerindeki değişimler açısından anlamlı bir ilişki saptanmamıştır. Tartışma: Bu çalışmada çocuk ve ergenlerde dislipidemi ve bir yıllık risperidon tedavisi arasında anlamlı bir ilişki saptanmamıştır. Literatürde gençlerde ve çocuklarda atipik antipsikotik tedavi sonrası lipid profili değişiklikleri ile ilgili çalışmalar sınırlı olduğundan, daha büyük örneklemlerde kontrollü çalışmalar yürütülerek varsa dislipidemi sıklığı ve risk etkenleri ortaya konulmalıdır.

Serum lipid profile due to risperidone treatment in child and youth patients

Objective: Atypical antipsychotics (AAPs) have been reported to cause metabolic dysregulation that may result in AAPs-related weight gain. The purpose of this study was to assess triglyceride, cholesterol and weight changes among risperidone-treated child and youths. Methods: Eighty subjects treated with risperidone for any psychiatric disturbances were included in the study. Fasting total low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, (HDL-C), total cholesterol (TC), and triglyceride (TG) levels were measured at baseline and at 12 months of treatment. Results: There was no significant difference between baseline mean levels of TG, TC, HDL-C and LDL-C and twelfth months mean levels of TG, TC, HDL-C and LDL-C (respectively p=0.341, p=0.135, p=0.414, p=0.411, p=0.707). Comparison of baseline and 12 months data with respect to the age groups were presented in table 2. There was no significant association with age, gender, risperidone dose and changes of serum TG, TC, LDL-C or HDL-C levels. Conclusion: In conclusion, this study did not identify significant associ-ations between dyslipidemia and one year risperidone treatment in children and adolescents. Because little long-term lipid profile follow-up is available with atypical antipsychotics treatment in youths, controlled studies in larger samples should be carried out to reveal the frequency and the risk factors of dyslipidemia.

PDF

___

1. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders and subaverage IQ. J Child Adolesc Psychopharmacol 2004; 14:243-254.
2. Zarcone JR, Hellings JA, CrandallK, Reese RM, Marquis J, Fle-ming K, et al. Effects of risperidone on aberrant behavior of per-sons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard 2001; 106:525-538.
3. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double blind study. Br J Psychiatry 2009; 194:158-164.
4. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduc-tion with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004; 43:206-214.
5. Biederman J, Mick E, Faraone SV, Wozniak J, Spencer T, Pandina G. Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: A post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study. Clin Ther 2006; 28:794-800.
6. American Diabetes Association, American Psychiatric Associa-tion, American Association of Clinical Endocrinologists & North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
7. Correll CU. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:9-20.
8. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45:771-791.
9. Correll CU, Penzner JB, Parikh UH, Mughal TB, Javed T, Carbon M, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15:177-206.
10. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and ris-peridone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002; 41:337-343.
11. Khan RA, Mican LM, Suehs BT. Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation. J Psychiatr Pract 2009; 15:320-328.
12. Vieweg WV, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 2005; 111:177-184.
13. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsy-chotic medications during firsttime use in children and adoles-cents. J Am Med Assoc 2009; 302:1765-1773.
14. Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med 2005; 352:2100-2109.
15. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 2009; 19:101-109.
16. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olan-zapine and risperidone. J Neural Transm 2008; 115:1599-1608.
17. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharma-col 1998; 8:151-159.
18. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, et al. Risperidone-associated weight gain in children and adoles-cents: a retrospective chart review. J Child Adolesc Psychophar-macol 2000; 10:259-268.
19. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical anti-psychotics. Am J Psychiatry 2003; 160:290-296.
20. Meyer JM. A retrospective comparison of weight, lipid, and glu-cose changes between risperidone-and olanzapine-treated inpa-tients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63:425-433.
21. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and halo-peridol. Schizophr Res 2003; 60:99-100.
22. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63:856-865.
23. Sikich L, Hamer RM, Bashford1 RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29:133-145.
24. Martin A, L'Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 2002; 11:129-133.
25. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 58:589-594.
26. Correll CU, Parikh UH, Mughal T, Kane JM, Malhotra AK. New-onset dyslipidemia in antipsychotic-naïve youngsters treated with atypical antipsychotics. Biol Psychiatry 2005; 57:36.
27. Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation anti-psychotics. J Clin Psychiatry 2008; 69:1166-1175.
28. Patel NC, Hariparsad M, Matias-Akthar M, Sorter MT, Barzman DH, Morrison JA, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical anti-psychotics. J Child Adolesc Psychopharmacol 2007; 17:303-311.
29. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164:1547-1556.
30. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior dis-orders and subaverage intelligence: Efficacy, safety, and tolera-bility. J Child Adolesc Psychopharmacol 2006; 16:260-272.
31. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S. Risperidone in children with disruptive behavior disor-ders and subaverage intelligence: A 1-year open label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005; 44:64-72.
32. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizo-phrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66:183-194.
33. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89:2583-2589.
34. Bouchard RH, Demers MF, Simoneau I, Almeras N, Villeneuve J, Mottard JP, et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 2001; 21:110-111.
35. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767-770.
36. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998; 338:1650-1656.
37. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005; 15:869-884.
38. Steiner H. Practice parameters for the assessment and treat-ment of children and adolescents with conduct disorders. J Am Acad Child Adolesc Psychiatry 1997; 36:122-139.